Our group uses a multidisciplinary approach to develop new drug candidates. We apply pharmacology, molecular biology, biochemistry, computer molecular modeling and nanotechnology methods in our research. We believe that an optimal drug-development project begins with a deep understanding of molecular pharmacology and choice of a key target protein which plays an important role in the pathogenesis of a specific disease. Then, based on computer molecular modeling and the 3D structure of the target protein, possible small organic molecules that might interact with the protein are identified in silico. Dozens of new molecules are then synthesized and tested in vitro in tissue culture, and finally the therapeutic effect of the lead compounds are investigated in animal models. All these steps we conduct in our lab.

Our research group aims to develop new drug candidates against several devastating human diseases. We believe that medicinal chemists have a chance to improve the health and well-being of human society.

ANTI OXIDATIVE DRUGS

​

Development of artificial pancreatic islets and enhancing beta cells functions based on a clustered nanoformulation of neuroligin-2 mimetics.